Skip to content

Impact of Bridging vs. Non-Bridging Therapeutic Strategies on In-Hospital Outcomes in Elderly Patients Undergoing Non-Cardiac Surgery After Coronary Stent Implantation: A Causal Inference Analysis Based on Target Trial Emulation

Impact of Bridging vs. Non-Bridging Therapeutic Strategies on In-Hospital Outcomes in Elderly Patients Undergoing Non-Cardiac Surgery After Coronary Stent Implantation: A Causal Inference Analysis Based on Target Trial Emulation

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600125952
Enrollment
Unknown
Registered
2026-06-01
Start date
2026-06-01
Completion date
Unknown
Last updated
2026-06-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronary Atherosclerotic Heart Disease

Interventions

Observation group:None

Sponsors

West China Hospital of Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
65 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Underwent PCI and had a coronary stent implanted within 12 months (360 days) prior to undergoing non-cardiac surgery. 2. Age >= 65 years (age at the time of PCI and coronary stent implantation is used as the reference). 3. Requires non-cardiac surgery (including elective or emergency surgery) within 12 months (360 days) after PCI for clinical reasons. 4. Has been regularly taking long-term antiplatelet therapy in the perioperative period (including aspirin, indobufen, and/or P2Y12 receptor inhibitors such as clopidogrel, ticagrelor, etc.).

Exclusion criteria

Exclusion criteria: 1. Patients who have been on long-term oral anticoagulant therapy before surgery (such as warfarin or novel oral anticoagulants); 2. Patients with conditions that may seriously affect the assessment of perioperative outcomes, including but not limited to: active bleeding before surgery or known coagulation disorders; stroke events within 30 days before surgery; advanced malignant tumors with an expected survival of less than 1 year; end-stage liver disease (Child-Pugh class C); 3. Patients for whom perioperative antiplatelet and bridging therapy strategies cannot be clearly classified based on past medical records; 4. Patients undergoing surgery under only local anesthesia or simple peripheral nerve blockade, without combined neuraxial or general anesthesia; 5. Patients with missing key study variables (such as perioperative antiplatelet management strategies or major outcome events) exceeding 20%, making reliable analysis impossible.

Design outcomes

Primary

MeasureTime frame
Composite endpoint of major adverse cardiovascular and cerebrovascular events (MACCE) occurring during hospitalization;

Secondary

MeasureTime frame
Unplanned reoperation;In-hospital all-cause death;Postoperative length of hospital stay (pLOS);ICU admission status;In-hospital clinically relevant bleeding events;

Countries

China

Contacts

Public ContactChen Lingmin

West China Hospital of Sichuan University

1010702289@qq.com+86 28 85421550

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026